Author(s): S. D. Mankar, Tanishka Pawar, Prerana Musale

Email(s): sdmankar655@gmail.com

DOI: 10.52711/2231-5675.2023.00034   

Address: S. D. Mankar, Tanishka Pawar, Prerana Musale
Pravara Rural College of Pharmacy, Pravaranagar, Tal: Rahta, Dist: Ahmednagar 413737, India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 3,     Year - 2023


ABSTRACT:
In the last 4 years, pharmacometrics (PMX) has advanced to the point that it is now a crucial part of drug development. Drug delivery systems and molecules with more complex architecture are being developed as technology advances. Pharmacodynamic modelling is based on the quantitative integration of pharmacokinetics, pharmacological systems, and (patho-) physiological processes in order to comprehend the intensity and time course of drug effects on the body. As a result, the drug absorption and disposition processes after the administration of these drug delivery systems and engineered molecules become exceedingly complex. The research field of drug delivery focuses on the development of new techniques to manipulate drug absorption and disposition to achieve a desirable effect for the PMX model used. An opportunity to combine pharmacokinetic and pharmacodynamic model-based estimations with pharmacoeconomic models emerges given the unpredictability in the dose-concentration-effect relationship of medications. Model-based drug development (MBDD) has been found to address the underlying causes of medication failure, hence enhancing the productivity, effectiveness, and success of late-stage clinical research. The pharmacokinetic (PK) model principles in optimizing the drug dose to suit individual patient needs and achieving maximum therapeutic utility are called clinical pharmacology. Pharmacodynamics (PD) relates response to the concentration of drugs in the body. Disease progression model-based evaluation of disease progression is an important aspect of drug development and pharmacology. The future perspective of pharmacometrics in drug development and clinical practices is challenging.


Cite this article:
S. D. Mankar, Tanishka Pawar, Prerana Musale. Pharmacometrics: Application in Drug Development and Clinical Practice. Asian Journal of Pharmaceutical Analysis. 2023; 13(3):210-6. doi: 10.52711/2231-5675.2023.00034

Cite(Electronic):
S. D. Mankar, Tanishka Pawar, Prerana Musale. Pharmacometrics: Application in Drug Development and Clinical Practice. Asian Journal of Pharmaceutical Analysis. 2023; 13(3):210-6. doi: 10.52711/2231-5675.2023.00034   Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-3-10


REFERENCES:
1.    Bhavatharini PA, Deepalakshmi M, Arun KP. Pharmacometrics: The science applied from bench to bedside. Journal of Applied Pharmaceutical Science. 2021 Dec 27; 12(1):055-64.
2.    Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. The Journal of Clinical Pharmacology. 2008 May; 48(5):632-49.
3.    Ette EI, Williams PJ, editors. Pharmacometrics: the science of quantitative pharmacology. John Wiley and Sons; 2013 Mar 14.
4.    Xu Y, Kimko H. Pharmacometrics: A quantitative decision-making tool in drug development. Quantitative Methods in Pharmaceutical Research and Development: Concepts and Applications. 2020:71-104.
5.    Koch G, Pfister M, Daunhawer I, Wilbaux M, Wellmann S, Vogt JE. Pharmacometrics and machine learning partner to advance clinical data analysis. Clinical Pharmacology and Therapeutics. 2020 Apr; 107(4):926-33.
6.    van der Graaf PH. CPT: pharmacometrics and systems pharmacology. CPT: Pharmacometrics and Systems Pharmacology. 2012 Sep; 1(9):1-4.
7.    Yeo KR, Hennig S, Krishnaswami S, Strydom N, Ayyar VS, French J, Sinha V, Sobie E, Zhao P, Friberg LE, Mentré F. CPT: Pharmacometrics and Systems Pharmacology–inception, maturation, and future vision. CPT: Pharmacometrics and Systems Pharmacology. 2021 Jul; 10(7):649.
8.    Lee SJ, Jeon S. A review of three years' experience of the first pharmacometrics company in Korea. Translational and Clinical Pharmacology. 2019 Dec; 27(4):149-54.
9.    Zheng QS, Li LJ. Pharmacometrics: a quantitative tool of pharmacological research. Acta Pharmacologica Sinica. 2012 Nov; 33(11):1337-8.
10.    Frigg R, Hartmann S. Models in science (Stanford encyclopedia of philosophy).
11.    Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model‐based drug development. CPT: Pharmacometrics and Systems Pharmacology. 2012 Sep; 1(9):1-4..
12.    Zhang XY, Trame MN, Lesko LJ, Schmidt S. Sobol sensitivity analysis: a tool to guide the development and evaluation of systems pharmacology models. CPT: Pharmacometrics and Systems Pharmacology. 2015 Feb; 4(2):69-79.
13.    Srinivasan M, White A, Chaturvedula A, Vozmediano V, Schmidt S, Plouffe L, Wingate LM. Incorporating pharmacometrics into pharmacoeconomic models: applications from drug development. Pharmacoeconomics. 2020 Oct; 38:1031-42.
14.    Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics: A treatise. Vallabh Prakashan. Edition 3, 238-247.
15.    Koch G, Pfister M, Daunhawer I, Wilbaux M, Wellmann S, Vogt JE. Pharmacometrics and machine learning partner to advance clinical data analysis. Clinical Pharmacology and Therapeutics. 2020; 107(4):926-33.
16.    Towers S. Introduction to compartmental modeling. Polymatheia. Archived from the original on December. 2013; 11.
17.    Perry C, Davis G, Conner TM, Zhang T. Utilization of physiologically based pharmacokinetic modeling in clinical pharmacology and therapeutics: an overview. Current Pharmacology Reports. 2020; 6:71-84.
18.    Rohatagi S, Kan S, Derendorf H. Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration. Die Pharmazie. 1997; 52(7):529-32.
19.    Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metabolism and Disposition. 2003; 31(5):510-8.
20.    Felmlee, M. A., Morris, M. E., and Mager, D. E. Mechanism-based pharmacodynamic modeling. Methods in molecular biology (Clifton, N.J.); 2012: 929, 583–600.
21.    Garralda E, Dienstmann R, Tabernero J. Pharmacokinetic /pharmacodynamic modeling for drug development in oncology. American Society of Clinical Oncology Educational Book. 2017; 37:210-5.
22.    Zou H, Banerjee P, Leung SS, Yan X. Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges. Frontiers in Pharmacology. 2020; 11: 997.
23.    Derendorf H, Meibohm B. Modeling of pharmacokinetic/ pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharmaceutical Research. 1999 Feb; 16:176-85.
24.    Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologics. Drug Discovery Today. 2007; 12(23-24):1018-24.
25.    Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends in Pharmacological Sciences. 2008; 29(4):186-91.
26.    Holford NH, Peace KE. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proceedings of the National Academy of Sciences. 1992; 89(23):11471-5.
27.    Barrett JS, Nicholas T, Azer K, Corrigan BW. Role of disease progression models in drug development. Pharmaceutical Research. 2022; 39(8):1803-15.
28.    Cook SF, Bies RR. Disease progression modeling: key concepts and recent developments. Current Pharmacology Reports. 2016 Oct; 2:221-30.
29.    Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharmaceutical Research. 1995; 12:1845-55.
30.    Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model‐based drug development. CPT: Pharmacometrics and Systems Pharmacology. 2012; 1(9):1-4.
31.    Brekkan A, Lopez-Lazaro L, Yngman G, Plan EL, Acharya C, Hooker AC, Kankanwadi S, Karlsson MO. A population pharmacokinetic-pharmacodynamic model of pegfilgrastim. The AAPS Journal. 2018; 20(5):91.
32.    Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy. 2011; 100(1):4-17.
33.    Powell JR, Cook J, Wang Y, Peck R, Weiner D. Drug dosing recommendations for all patients: a roadmap for change. Clinical Pharmacology and Therapeutics. 2021; 109(1):65-72.
34.    Williams PJ, Ette EI. Pharmacometrics: impacting drug development and pharmacotherapy. Pharmacometrics: The Science of Quantitative Pharmacology. 2007 Mar 23:1-21.
35.    Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. Pharmacokinetics/ pharmacodynamics and the stages of drug development: role of modeling and simulation. The AAPS Journal. 2005 ; 7:E544-59.
36.    Ella R Assessment of Pharmacometrics and Clinical Pharmacy. J Pharma Reports. 2022; 06:153.
37.    Aarons L, Karlsson MO, Mentré F, Rombout F, Steimer JL, van Peer A. Role of modelling and simulation in Phase I drug development. European Journal of Pharmaceutical Sciences. 2001; 13(2):115-22.
38.    Sheiner LB. Learning versus confirming in clinical drug development. Clinical Pharmacology and Therapeutics. 1997; 61(3): 275-91.
39.    Alsultan A, Alghamdi WA, Alghamdi J, Alharbi AF, Aljutayli A, Albassam A, Almazroo O, Alqahtani S. Clinical pharmacology applications in clinical drug development and clinical care: a focus on Saudi Arabia. Saudi Pharmaceutical Journal. 2020; 28(10): 1217-27.




Recomonded Articles:

Author(s): Paras Virani, Rajanit Sojitra, Hasumati Raj, Vineet Jain

DOI: 10.5958/2231-5675.2015.00025.3         Access: Open Access Read More

Author(s): Nitin A. Gaikwad, Abhishek S. Pujari, Indrajeet V. Mane, Ganesh B. Vambhurkar, Pravin P. Honmane

DOI: 10.5958/2231-5675.2018.00024.8         Access: Open Access Read More

Author(s): Duggi Adilakshmi, Abdul Saleem Mohammad, Nuha Rasheed, Kathula Umadevi, Chandana Pasupuleti

DOI: 10.5958/2231-5675.2016.00025.9         Access: Open Access Read More

Author(s): Gajanan Darwhekar, Priya Jain, Dinesh Kumar Jain, Gaurav Agrawal

DOI:         Access: Open Access Read More

Author(s): Arshiya Zulfeen Mohd Fahim, Mohammed Shakir Ghouse, Syed Qumarul Islam, Mohammed Abdul Mughni Danish, Shaikh Mehmood, Shaikh Saniya, Quraishi Inshrah Fatima

DOI: 10.52711/2231-5675.2021.00018         Access: Open Access Read More

Author(s): Akhilesh Gupta, Vimal Yadav, Jaydeep S. Yadav, Swati Rawat

DOI:         Access: Open Access Read More

Author(s): Krishna Kondragunta. V, Karuppuraj. V, Perumal. K

DOI:         Access: Open Access Read More

Author(s): Chandana Pasupuleti, Abdul Saleem Mohammad, Nuha Rasheed, Kathula Umadevi, Duggi Adilakshmi

DOI: 10.5958/2231-5675.2016.00026.0         Access: Open Access Read More

Author(s): Amruta S. Kadam, Nayana V. Pimpodkar, Puja S.Gaikwad, Sushila D. Chavan.

DOI:         Access: Open Access Read More

Author(s): Sudhanshu I Chauhan, Pankaj D. Savani, Hasumati Raj, Sagar Patel

DOI: 10.5958/2231-5675.2016.00009.0         Access: Open Access Read More

Author(s): Nuha Rasheed, Abdul Saleem Mohammad, Hajera Hafeez, Seema Farheen

DOI: 10.5958/2231-5675.2017.00028.X         Access: Open Access Read More

Author(s): Swapnil D. Jadhav, Akshay A. Magdum, Ramchandra M. Panchal , Pradip S. Koli

DOI:         Access: Open Access Read More

Author(s): Dibyajyoti Saha, Swati Paul

DOI:         Access: Open Access Read More

Author(s): Dr. Bharti Ahirwar

DOI:         Access: Open Access Read More

Asian Journal of Pharmaceutical Analysis (AJPA) is an international, peer-reviewed journal, devoted to pharmaceutical analysis...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231–5675 


Recent Articles




Tags